We are live on ! Find out more
BCAB icon

BioAtla
BCAB

87 hedge funds and large institutions have $96.1M invested in BioAtla in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 13

90% more call options, than puts

Call options by funds: $55K | Put options by funds: $29K

42% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 19

10% more funds holding

Funds holding: 79 → 87 (+8)

10% more capital invested

Capital invested by funds: $87.6M → $96.1M (+$8.51M)

0.03% less ownership

Funds ownership: 1.37% → 1.34% (-0.03%)

Holders
87
Holders Change
+8
Holders Change %
+10.13%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
28
Reduced
13
Closed
19
Calls
$55K
Puts
$29K
Net Calls
+$26K
Net Calls Change
+$7K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.62M
2
State Street
State Street
Massachusetts
+$1.99M
3
Norges Bank
Norges Bank
Norway
+$1.68M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.57M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$9.3M
2
CS
Candriam SCA
Luxembourg
-$3.86M
3
APM
Avidity Partners Management
Texas
-$1.61M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.31M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$979K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Soleus Capital Management
Connecticut
$13M – – –
TCM
2
Tang Capital Management
California
$11M +$172K +1,000 +1%
BlackRock
3
BlackRock
New York
$9.6M +$7.62M +44,306 +225%
Vanguard Group
4
Vanguard Group
Pennsylvania
$6.29M +$600K +3,486 +9%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$5.68M +$1.03M +6,000 +19%
Morgan Stanley
6
Morgan Stanley
New York
$5.08M -$642K -3,732 -10%
WA
7
Wasatch Advisors
Utah
$4.5M +$801K +4,656 +18%
CAM
8
Cormorant Asset Management
Massachusetts
$3.54M – – –
O
9
OrbiMed
New York
$3.47M -$9.3M -54,096 -70%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.49M +$1.57M +9,113 +121%
Massachusetts Financial Services
11
Massachusetts Financial Services
Massachusetts
$2.27M -$37K -215 -1%
State Street
12
State Street
Massachusetts
$2.14M +$1.99M +11,581 +435%
Deutsche Bank
13
Deutsche Bank
Germany
$2.08M – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$2.06M +$787K +4,577 +50%
BC
15
Boxer Capital
California
$2.06M – – –
VC
16
Vivo Capital
California
$1.91M – – –
Vontobel Holding
17
Vontobel Holding
Switzerland
$1.7M +$46.4K +270 +2%
SAM
18
Sectoral Asset Management
Quebec, Canada
$1.67M +$46.4K +270 +2%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
19
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.54M – – –
Norges Bank
20
Norges Bank
Norway
$1.46M +$1.68M +9,764 New
UOC
21
UBS O'Connor
Illinois
$1.21M +$542K +3,153 +64%
Northern Trust
22
Northern Trust
Illinois
$1.09M +$944K +5,488 +304%
AAA
23
Affinity Asset Advisors
New York
$975K – – –
Two Sigma Advisers
24
Two Sigma Advisers
New York
$907K -$171K -996 -14%
Millennium Management
25
Millennium Management
New York
$855K +$349K +2,028 +55%
1
2 3 4 5

BCAB Hedge Fund Activity: Q2 2023 in Review

87 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q2 2023, worth a combined $96.1M — up 9.7% from $87.6M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new BCAB positions and 19 closed out — a net gain of 8 holders — while 28 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $7.62M. The largest seller was OrbiMed, cutting an estimated $9.3M.

  • 87 institutional investors held BioAtla (BCAB) as of Q2 2023, up from 79 in Q1 2023.
  • Funds reported $96.1M of BioAtla stock for Q2 2023, up 9.7% quarter-over-quarter.
  • 27 funds opened new BioAtla positions in Q2 2023 and 19 closed out, a net change of +8 holders.
  • The largest BioAtla buyer in Q2 2023 was BlackRock, an estimated $7.62M added.
  • The largest BioAtla seller in Q2 2023 was OrbiMed, an estimated $9.3M sold.

Based on aggregated 13F filings for Q2 2023.